Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 118
Filter
1.
Article in English | MEDLINE | ID: mdl-38780970

ABSTRACT

An 18-year-old male with no significant medical history presented for evaluation of a nasal papule that was asymptomatic without any associated pain, pruritus, or bleeding with no changes for a year. What is your diagnosis?

3.
JAMA Dermatol ; 160(3): 341-350, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38324292

ABSTRACT

Importance: Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact. Objective: To explore factors associated with AA severity beyond scalp hair loss, and to support the development of the Alopecia Areata Severity and Morbidity Index (ASAMI). Evidence Review: A total of 74 hair and scalp disorder specialists from multiple continents were invited to participate in an eDelphi project consisting of 3 survey rounds. The first 2 sessions took place via a text-based web application following the Delphi study design. The final round took place virtually among participants via video conferencing software on April 30, 2022. Findings: Of all invited experts, 64 completed the first survey round (global representation: Africa [4.7%], Asia [9.4%], Australia [14.1%], Europe [43.8%], North America [23.4%], and South America [4.7%]; health care setting: public [20.3%], private [28.1%], and both [51.6%]). A total of 58 specialists completed the second round, and 42 participated in the final video conference meeting. Overall, consensus was achieved in 96 of 107 questions. Several factors, independent of the Severity of Alopecia Tool score, were identified as potentially worsening AA severity outcomes. These factors included a disease duration of 12 months or more, 3 or more relapses, inadequate response to topical or systemic treatments, rapid disease progression, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes, and/or beard), nail involvement, impaired quality of life, and a history of anxiety, depression, or suicidal ideation due to or exacerbated by AA. Consensus was reached that the Alopecia Areata Investigator Global Assessment scale adequately classified the severity of scalp hair loss. Conclusions and Relevance: This eDelphi survey study, with consensus among global experts, identified various determinants of AA severity, encompassing not only scalp hair loss but also other outcomes. These findings are expected to facilitate the development of a multicomponent severity tool that endeavors to competently measure disease impact. The findings are also anticipated to aid in identifying candidates for current and emerging systemic treatments. Future research must incorporate the perspectives of patients and the public to assign weight to the domains recognized in this project as associated with AA severity.


Subject(s)
Alopecia Areata , Humans , Alopecia/diagnosis , Alopecia Areata/diagnosis , Consensus , Morbidity , Quality of Life
8.
Front Pharmacol ; 12: 602206, 2021.
Article in English | MEDLINE | ID: mdl-33995009

ABSTRACT

Tyrosinase (TYR) is a copper-containing monooxygenase central to the function of melanocytes. Alterations in its expression or activity contribute to variations in skin, hair and eye color, and underlie a variety of pathogenic pigmentary phenotypes, including several forms of oculocutaneous albinism (OCA). Many of these phenotypes are linked to individual missense mutations causing single nucleotide variants and polymorphisms (SNVs) in TYR. We previously showed that two TYR homologues, TYRP1 and TYRP2, modulate TYR activity and stabilize the TYR protein. Accordingly, to investigate whether TYR, TYRP1, and TYRP2 are biophysically compatible with various heterocomplexes, we computationally docked a high-quality 3D model of TYR to the crystal structure of TYRP1 and to a high-quality 3D model of TYRP2. Remarkably, the resulting TYR-TYRP1 heterodimer was complementary in structure and energy with the TYR-TYRP2 heterodimer, with TYRP1 and TYRP2 docking to different adjacent surfaces on TYR that apposed a third realistic protein interface between TYRP1-TYRP2. Hence, the 3D models are compatible with a heterotrimeric TYR-TYRP1-TYRP2 complex. In addition, this heterotrimeric TYR-TYRP1-TYRP2 positioned the C-terminus of each folded enzymatic domain in an ideal position to allow their C-terminal transmembrane helices to form a putative membrane embedded three-helix bundle. Finally, pathogenic TYR mutations causing OCA1A, which also destabilize TYR biochemically, cluster on an unoccupied protein interface at the periphery of the heterotrimeric complex, suggesting that this may be a docking site for OCA2, an anion channel. Pathogenic OCA2 mutations result in similar phenotypes to those produced by OCA1A TYR mutations. While this complex may be difficult to detect in vitro, due to the complex environment of the vertebrate cellular membranous system, our results support the existence of a heterotrimeric complex in melanogenesis.

9.
Pediatr Dermatol ; 38(5): 1127-1131, 2021 Sep.
Article in English | MEDLINE | ID: mdl-33870556

ABSTRACT

BACKGROUND/OBJECTIVES: To investigate the evaluation and management of atopic dermatitis (AD) in the pediatric emergency department (PED). METHODS: This retrospective chart review was performed at the PED of a single institution and examined data from 2012 to 2017. Of 335 visits from patients 18 years and younger coded for AD, 167 visits with documented findings that supported a diagnosis of AD according to guidelines from the American Academy of Dermatology were included. RESULTS: The mean age of presentation was 6.3 years (standard deviation [SD]: 5.9). Of 11 patients with multiple visits, the mean between-visit interval was 31 days (SD: 41). Topical corticosteroids (TCSs) were not prescribed or recommended in 63/167 visits. In an additional 46/167 visits, over-the-counter topical hydrocortisone was recommended. Of prescribed TCS, the mean TCS class was 5.5 (SD: 1.9). 61/104 recommended or prescribed TCSs were weak (Class 7), the most likely used class (P < .001). Dermatology consultation was requested in 14/167 visits and was associated with higher rates of TCS prescriptions (13/14 vs 91/153, P = .018), a higher mean class of TCS prescribed (3.1 vs 5.9, P < .001), higher prescription rates of systemic antibiotics (8/14 vs 10/153, P < .001), and higher recommendation rates for emollient usage (10/14 vs 46/153, P = .005). CONCLUSIONS: Most patients presenting to the PED for AD were either not prescribed a TCS or were prescribed a weak TCS, often one that is over-the-counter. While there may be a variety of explanations for these findings, it is possible they reveal a practice gap regarding AD management in the PED.


Subject(s)
Dermatitis, Atopic , Adrenal Cortex Hormones/therapeutic use , Child , Dermatitis, Atopic/drug therapy , Emergency Service, Hospital , Emollients/therapeutic use , Humans , Retrospective Studies
10.
JAMA Dermatol ; 157(4): 1-11, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33656556

ABSTRACT

Importance: A recent expert consensus exercise emphasized the importance of developing a global network of patient registries for alopecia areata to redress the paucity of comparable, real-world data regarding the effectiveness and safety of existing and emerging therapies for alopecia areata. Objective: To generate core domains and domain items for a global network of alopecia areata patient registries. Evidence Review: Sixty-six participants, representing physicians, patient organizations, scientists, the pharmaceutical industry, and pharmacoeconomic experts, participated in a 3-round eDelphi process, culminating in a face-to-face meeting at the World Congress of Dermatology, Milan, Italy, June 14, 2019. Findings: Ninety-two core data items, across 25 domains, achieved consensus agreement. Twenty further noncore items were retained to facilitate data harmonization in centers that wish to record them. Broad representation across multiple stakeholder groups was sought; however, the opinion of physicians was overrepresented. Conclusions and Relevance: This study identifies the domains and domain items required to develop a global network of alopecia areata registries. These domains will facilitate a standardized approach that will enable the recording of a comprehensive, comparable data set required to oversee the introduction of new therapies and harness real-world evidence from existing therapies at a time when the alopecia areata treatment paradigm is being radically and positively disrupted. Reuse of similar, existing frameworks in atopic dermatitis, produced by the Treatment of Atopic Eczema (TREAT) Registry Taskforce, increases the potential to reuse existing resources, creates opportunities for comparison of data across dermatology subspecialty disease areas, and supports the concept of data harmonization.


Subject(s)
Alopecia Areata/epidemiology , Alopecia Areata/therapy , Registries , Alopecia Areata/diagnosis , Consensus , Delphi Technique , Humans , Internationality , Severity of Illness Index , Surveys and Questionnaires
11.
J Am Acad Dermatol ; 85(4): 878-884, 2021 10.
Article in English | MEDLINE | ID: mdl-33727021

ABSTRACT

BACKGROUND: The association between isotretinoin and psychiatric disturbance, including depression and suicidal behavior, is controversial. OBJECTIVE: To investigate whether acne patients prescribed isotretinoin or antibiotics were more likely to have psychiatric disorders and/or engage in suicidal behavior. METHODS: Retrospective cohort study using the IBM MarketScan Research Databases, which contain commercial insurance claims in the United States, to identify acne patients who were prescribed isotretinoin or oral antibiotics between 2011 and 2017 and who were diagnosed with psychiatric disorders or suicidal behavior. RESULTS: A total of 72,555 patients were included in the study. Patients in the general population were 1.47 times more likely to be diagnosed with suicidal ideation or attempt compared to acne patients prescribed isotretinoin (adjusted odds ratio [OR] 1.47; confidence interval [95% CI], 1.27, 1.70; P < .0001). The general population (adjusted OR 0.87; 95% CI, 0.84, 0.89; P < .0001) and acne patients prescribed antibiotics (adjusted OR 0.88; 95% CI, 0.85, 0.91; P < .0001) were less likely to have a psychiatric diagnosis compared to acne patients prescribed isotretinoin. The prevalence of suicidal behavior during isotretinoin treatment was lower (0.10%; P = .082) than in the year prior to isotretinoin treatment (0.22%) and in the year following treatment (0.34%; P = .004). LIMITATIONS: The study excluded individuals with public insurance and those who were uninsured, and the data in the study relied on the accuracy of the medical coding. CONCLUSIONS: Compared to the general population, acne patients prescribed isotretinoin were less likely to engage in suicidal behavior. Further exploration into the slight increase in suicidal behavior seen in isotretinoin patients 1 year after therapy is warranted.


Subject(s)
Acne Vulgaris , Dermatologic Agents , Insurance , Mental Disorders , Acne Vulgaris/drug therapy , Acne Vulgaris/epidemiology , Anti-Bacterial Agents/adverse effects , Dermatologic Agents/adverse effects , Humans , Isotretinoin/adverse effects , Mental Disorders/drug therapy , Mental Disorders/epidemiology , Retrospective Studies , Suicidal Ideation , United States/epidemiology
12.
JAMA Dermatol ; 157(2): 207-212, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33295957

ABSTRACT

Importance: To date, no study has characterized the mucocutaneous features seen in hospitalized children with multisystem inflammatory syndrome in children (MIS-C) or the temporal association of these findings with the onset of systemic symptoms. Objective: To describe the mucocutaneous findings seen in children with MIS-C during the height of the coronavirus disease 2019 (COVID-19) pandemic in New York City in 2020. Design, Setting, and Participants: A retrospective case series was conducted of 35 children admitted to 2 hospitals in New York City between April 1 and July 14, 2020, who met Centers for Disease Control and Prevention and/or epidemiologic criteria for MIS-C. Main Outcomes and Measures: Laboratory and clinical characteristics, with emphasis on mucocutaneous findings, of children who met criteria for MIS-C. The characterization of mucocutaneous features was verified by 2 board-certified pediatric dermatologists. Results: Twenty-five children (11 girls [44%]; median age, 3 years [range, 0.7-17 years]) were identified who met definitional criteria for MIS-C; an additional 10 children (5 girls [50%]; median age, 1.7 years [range, 0.2-15 years]) were included as probable MIS-C cases (patients met all criteria with the exception of laboratory test evidence of severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infection or known exposure). The results of polymerase chain reaction tests for SARS-CoV-2 were positive for 10 patients (29%), and the results of SARS-CoV-2 immunoglobulin G tests were positive for 19 patients (54%). Of the 35 patients, 29 (83%) exhibited mucocutaneous changes, with conjunctival injection (n = 21), palmoplantar erythema (n = 18), lip hyperemia (n = 17), periorbital erythema and edema (n = 7), strawberry tongue (n = 8), and malar erythema (n = 6) being the most common findings. Recognition of mucocutaneous findings occurred a mean of 2.7 days (range, 1-7 days) after the onset of fever. The duration of mucocutaneous findings varied from hours to days (median duration, 5 days [range, 0-11 days]). Neither the presence nor absence of mucocutaneous findings was significantly associated with overall disease severity. Conclusions and Relevance: In this case series of hospitalized children with suspected MIS-C during the COVID-19 pandemic, a wide spectrum of mucocutaneous findings was identified. Despite their protean and transient nature, these mucocutaneous features serve as important clues in the recognition of MIS-C.


Subject(s)
COVID-19/complications , Skin Diseases/etiology , Systemic Inflammatory Response Syndrome/complications , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Male , Mucous Membrane , New York City , Retrospective Studies
13.
J Am Acad Dermatol ; 84(6): 1594-1601, 2021 Jun.
Article in English | MEDLINE | ID: mdl-32926985

ABSTRACT

BACKGROUND: We previously reported the Alopecia Areata Consensus of Experts study, which presented results of an international expert opinion on treatments for alopecia areata. OBJECTIVE: To report the results of the Alopecia Areata Consensus of Experts international expert opinion on diagnosis and laboratory evaluation for alopecia areata. METHODS: Fifty hair experts from 5 continents were invited to participate in a 3-round Delphi process. Consensus threshold was set at greater than or equal to 66%. RESULTS: Of 148 questions, expert consensus was achieved in 82 (55%). Round 1 consensus was achieved in 10 of 148 questions (7%). Round 2 achieved consensus in 47 of 77 questions (61%). The final face-to-face achieved consensus in 25 of 32 questions (78%). Consensus was greatest for laboratory evaluation (12 of 14 questions [86%]), followed by diagnosis (11 of 14 questions [79%]) of alopecia areata. Overall, etiopathogenesis achieved the least category consensus (31 of 68 questions [46%]). LIMITATIONS: The study had low representation from Africa, South America, and Asia. CONCLUSION: There is expert consensus on aspects of epidemiology, etiopathogenesis, clinical features, diagnosis, laboratory evaluation, and prognostic indicators of alopecia areata. The study also highlights areas where future clinical research could be directed to address unresolved hypotheses in alopecia areata patient care.


Subject(s)
Alopecia Areata/diagnosis , Consensus , Dermatology/standards , Global Burden of Disease , Alopecia Areata/epidemiology , Alopecia Areata/etiology , Alopecia Areata/therapy , Comorbidity , Delphi Technique , Dermatology/methods , Dermoscopy , Hair Follicle/diagnostic imaging , Hair Follicle/growth & development , Hair Follicle/pathology , Humans , International Cooperation , Practice Guidelines as Topic , Prognosis , Risk Factors , Severity of Illness Index
14.
Pediatr Dermatol ; 38(1): 45-49, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32767593

ABSTRACT

BACKGROUND/OBJECTIVE: Papular scars are a recently described clinical phenotype of acne scarring characterized by papules occurring on the nose and chin. We have observed a similar presentation of nasal papules among patients seen in our clinic for acne and sought to further characterize the clinical and histopathological characteristics of this entity. METHODS: In this single-site case series, a retrospective review of electronic medical records of patients with nasal papules in association with acne vulgaris between April 2018 and April 2019 was performed. Clinical and histopathologic findings were recorded. RESULTS: We identified 20 patients who presented with a similar clinical phenotype of predominantly skin-colored, dome-shaped papules concentrated on the nose and chin in association with a history of more classic facial acne vulgaris. Papular lesions were seen predominately in adolescent Hispanic males. Concomitant acne on other areas of the face was identified in 18 patients at presentation while two patients had a history of adolescent acne. Biopsies were performed for five patients. Histopathologic examination demonstrated features of fibrosis and dilated thin-walled blood vessels, typical of angiofibromas. CONCLUSION: We present a series of adolescent patients with large, flesh-colored to erythematous papules seen predominantly on the nose. These lesions are histologically indistinguishable from angiofibromas and may represent an under-recognized yet disfiguring sequela of acne that may disproportionately affect adolescents with skin of color.


Subject(s)
Acne Vulgaris , Angiofibroma , Acne Vulgaris/diagnosis , Adolescent , Angiofibroma/diagnosis , Humans , Male , Nose , Retrospective Studies , Skin
15.
J Drugs Dermatol ; 19(7): 742-745, 2020 Jul 01.
Article in English | MEDLINE | ID: mdl-32721140

ABSTRACT

Introduction: Recent research on vitamin D has shown that the fat-soluble micronutrient has anti-microbial, anti-inflammatory, and anti-proliferative effects in cells and tissues. During wound healing, abnormal scarring may occur and lead to reduced mobility, disfigurement, and psychosocial concerns. The role of vitamin D in the pathogenesis and treatment of scarring has not been reviewed previously. Methods: A literature search was performed on PubMed to identify articles on vitamin D and keloid, hypertrophic, or burn scars. Results: Molecular, epidemiological, and human clinical studies are discussed. Overall, the evidence suggests lower levels of vitamin D precursors, the active metabolite, and receptor, are associated with increased risk of scar development and increased severity. Conclusions: Scars are challenging to treat, and patients are increasingly interested in non-invasive treatment options. Although few human clinical studies have been reported, vitamin D may be beneficial as an adjunct therapy to current treatment options. J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.4986.


Subject(s)
Cicatrix/therapy , Vitamin D Deficiency/diet therapy , Vitamin D/administration & dosage , Vitamins/administration & dosage , Wound Healing/physiology , Cicatrix/diagnosis , Cicatrix/etiology , Cicatrix/pathology , Combined Modality Therapy/methods , Fibroblasts/metabolism , Fibroblasts/pathology , Humans , Randomized Controlled Trials as Topic , Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism , Severity of Illness Index , Skin/cytology , Skin/pathology , Treatment Outcome , Vitamin D/blood , Vitamin D/metabolism , Vitamin D Deficiency/blood , Vitamin D Deficiency/complications , Vitamin D Deficiency/genetics , Vitamins/blood , Vitamins/metabolism , Wound Healing/drug effects
16.
J Am Acad Dermatol ; 83(1): 123-130, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32165196

ABSTRACT

BACKGROUND: A systematic review failed to identify any systemic therapy used in alopecia areata (AA) where use is supported by robust evidence from high-quality randomized controlled trials. OBJECTIVE: To produce an international consensus statement on the use and utility of various treatments for AA. METHODS: Fifty hair experts from 5 continents were invited to participate in a 3-round Delphi process. Agreement of 66% or greater was considered consensus. RESULTS: In the first round, consensus was achieved in 22 of 423 (5%) questions. After a face-to-face meeting in round 3, overall, consensus was achieved for only 130 (33%) treatment-specific questions. There was greater consensus for intralesional treatment of AA (19 [68%]) followed by topical treatment (25 [43%]). Consensus was achieved in 45 (36%) questions pertaining to systemic therapies in AA. The categories with the least consensus were phototherapy and nonprescription therapies. LIMITATIONS: The study included a comprehensive list of systemic treatments for AA but not all treatments used. CONCLUSION: Despite divergent opinions among experts, consensus was achieved on a number of pertinent questions. The concluding statement also highlights areas where expert consensus is lacking and where an international patient registry could enable further research.


Subject(s)
Alopecia Areata/therapy , Administration, Oral , Administration, Topical , Adrenal Cortex Hormones/therapeutic use , Age Factors , Alopecia Areata/drug therapy , Combined Modality Therapy , Complementary Therapies , Delphi Technique , Dermatologic Agents/therapeutic use , Expert Testimony , Humans , Injections, Intralesional , Phototherapy , Severity of Illness Index , Treatment Outcome
17.
Pediatr Dermatol ; 36(4): 520-523, 2019 Jul.
Article in English | MEDLINE | ID: mdl-31124168

ABSTRACT

Well-known causes of zinc deficiency, also referred to as acrodermatitis enteropathica (AE), include defects in intestinal zinc transporters and inadequate intake, but a rare cause of acquired zinc deficiency discussed here is an iatrogenic nutritional deficiency caused by parenteral nutrition administered without trace elements. While zinc-depleted parenteral nutrition causing dermatosis of acquired zinc deficiency was first reported in the 1990s, it is now again relevant due to a national vitamin and trace element shortage. A high index of suspicion may be necessary to diagnose zinc deficiency, particularly because early clinical findings are nonspecific. We present this case of acquired zinc deficiency in a patient admitted to a pediatric intensive care unit for respiratory distress and atypical pneumonia, who subsequently developed a severe bullous eruption due to iatrogenic zinc deficiency but was treated effectively with enteral and parenteral zinc supplementation, allowing for rapid re-epithelialization of previously denuded skin.


Subject(s)
Acrodermatitis/diagnosis , Malnutrition/diagnosis , Parenteral Nutrition, Total/adverse effects , Zinc/deficiency , Acrodermatitis/drug therapy , Acrodermatitis/etiology , Acrodermatitis/pathology , Biopsy, Needle , Child , Emergency Service, Hospital , Humans , Iatrogenic Disease , Immunohistochemistry , Intensive Care Units , Male , Malnutrition/etiology , Multimorbidity , Parenteral Nutrition, Total/methods , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/therapy , Prognosis , Rare Diseases , Respiratory Insufficiency/diagnosis , Respiratory Insufficiency/therapy , Risk Assessment , Treatment Outcome , Zinc/administration & dosage
18.
Cutis ; 102(5): 370-372, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30566538

ABSTRACT

Tinea incognito (TI) describes a common dermatophytosis with often atypical clinical features attributed to inappropriate use of topical immunomodulatory agents, usually corticosteroids. Given the high prevalence of TI and limited literature detailing this condition, we conducted a retrospective review of cases of pediatric dermatophytosis presenting to the Faculty Group Practice of the Ronald O. Perelman Department of Dermatology, New York University School of Medicine (New York, New York), between 2005 and 2016. Among microbiologically confirmed dermatophytosis cases, we found that even with prior treatment, TI often presented with classic features of tinea such as annularity and scale. The majority of cases were treated with oral antifungals, though some were treated with topical antifungals alone. This case series underscores the need to maintain a high clinical suspicion for TI.


Subject(s)
Tinea/epidemiology , Adolescent , Antifungal Agents/administration & dosage , Antifungal Agents/therapeutic use , Child , Child Health Services , Child, Preschool , Female , Humans , Infant , Male , Medical Records , New York City/epidemiology , Prevalence , Retrospective Studies , Tinea/drug therapy , Tinea/etiology , Urban Population
19.
Am J Clin Dermatol ; 19(5): 733-757, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30043128

ABSTRACT

Keratosis pilaris is a common skin disorder comprising less common variants and rare subtypes, including keratosis pilaris rubra, erythromelanosis follicularis faciei et colli, and the spectrum of keratosis pilaris atrophicans. Data, and critical analysis of existing data, are lacking, so the etiologies, pathogeneses, disease associations, and treatments of these clinical entities are poorly understood. The present article aims to fill this knowledge gap by reviewing literature in the PubMed, EMBASE, and CINAHL databases and providing a comprehensive, analytical summary of the clinical characteristics and pathophysiology of keratosis pilaris and its subtypes through the lens of disease associations, genetics, and pharmacologic etiologies. Histopathologic, genomic, and epidemiologic evidence points to keratosis pilaris as a primary disorder of the pilosebaceous unit as a result of inherited mutations or acquired disruptions in various biomolecular pathways. Recent data highlight aberrant Ras signaling as an important contributor to the pathophysiology of keratosis pilaris and its subtypes. We also evaluate data on treatments for keratosis pilaris and its subtypes, including topical, systemic, and energy-based therapies. The effectiveness of various types of lasers in treating keratosis pilaris and its subtypes deserves wider recognition.


Subject(s)
Abnormalities, Multiple/therapy , Darier Disease/therapy , Dermabrasion/methods , Dermatologic Agents/therapeutic use , Eyebrows/abnormalities , Phototherapy/methods , Abnormalities, Multiple/diagnosis , Abnormalities, Multiple/etiology , Abnormalities, Multiple/pathology , Administration, Cutaneous , Darier Disease/diagnosis , Darier Disease/etiology , Darier Disease/pathology , Dermatitis, Atopic/complications , Diagnosis, Differential , Eyebrows/pathology , Filaggrin Proteins , Humans , Ichthyosis/complications , Ichthyosis/genetics , Intermediate Filament Proteins/genetics , Mutation , Signal Transduction/genetics , Skin/pathology , Treatment Outcome , ras Proteins/genetics , ras Proteins/metabolism
20.
Am J Clin Dermatol ; 19(3): 449-455, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29556985

ABSTRACT

BACKGROUND: Little is known about how dermatologists prescribe hormonal antiandrogen acne treatment (HAAT). OBJECTIVE: The aim of this study was to investigate dermatologists' HAAT-prescribing habits and HAAT's impact on systemic antibiotic use in women with acne. METHODS: We performed a retrospective study at an academic medical center of female patients receiving HAAT (combined oral contraceptive [COC], spironolactone) for acne from January 2005 to October 2015. Data from a control group of female acne patients who never received HAAT were also collected. RESULTS: A total of 672 female patients received HAAT. Out of all systemic medications for acne, antibiotics were used as first-line treatment in 39% of patients, COCs in 12%, and spironolactone in 21%. Mean antibiotic durations in patients who initiated HAAT for the first time at the study site (250.4 days) were significantly longer than in patients who received HAAT prior to presentation and continued HAAT at the study site (192.0 days) (p = 0.021). A statistically significant inverse association was found between HAAT use and mean antibiotic duration (p = 0.016). CONCLUSIONS: HAAT is not typically used as a first-line systemic therapy in women with acne. HAAT usage is associated with shorter cumulative antibiotic durations and early HAAT initiation can decrease systemic antibiotic use in acne treatment.


Subject(s)
Acne Vulgaris/drug therapy , Androgen Antagonists/therapeutic use , Contraceptives, Oral, Combined/therapeutic use , Drug Prescriptions/statistics & numerical data , Spironolactone/therapeutic use , Adolescent , Adult , Anti-Bacterial Agents/therapeutic use , Cross-Sectional Studies , Female , Humans , Middle Aged , Retrospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...